Parexel International Corp., a Waltham biotechnology services company, said Thursday that it has purchased the software maker Liquent Inc. for $72 million.
Liquent, based in Horsham, Pa., makes software used by drug companies to manage regulatory submissions and product registrations. The purchase of Liquent will allow Parexel to expand the consulting services it provides to biotech and medical device companies.
Liquent has more than 200 clients worldwide that use its software. Prior to the sale, Liquent was owned by the private equity firm Marlin Equity Partners, of Hermosa Beach, Calif.
With the addition of Liquent, Parexel increased its revenue projection for the 2013 fiscal year from between $1.63 billion and $1.66 billion to between $1.675 billion and $1.695 billion.
Parexel helps biotech companies with the drug-development and launch processes, and helps to maximize sales after drugs become available. The company employs about 14,000 people in 51 countries.